Company: CERO
Filing Date: 2025-07-21
Form Type: S-1
Source: 0001213900-25-066152
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-21
Form: S-1
Chunk 3
---
 of the shares of our Common Stock by Keystone. Additionally, we will not receive any proceeds from the issuance or sale of the Keystone Commitment Shares. We may receive up to $25.0 million in aggregate gross proceeds from Keystone under the Keystone Purchase Agreements in connection with sales of the shares of our Common Stock to Keystone pursuant to the Keystone Purchase Agreements, including the Old Keystone Purchase Shares and any shares of our Common Stock sold after the date of this prospectus. However, the actual proceeds from Keystone may be less than this amount depending on the number of shares of our Common Stock sold and the price at which the shares of our Common Stock are sold. As of June 30, 2025, there were 2,126,003 shares of Common Stock outstanding on a fully-diluted basis after giving effect to the conversion of all outstanding Preferred Shares (as defined below), the exercise of all outstanding Warrants and options, and options available for issuance pursuant to our 2024 Plan and 2024 ESPP Plan, as amended from time to time, of which 1,994,227 shares were held by non-affiliates (without taking into account beneficial ownership or stock exchange limitations). If all of the 12,500,000 shares of our Common Stock offered for resale by Keystone under this prospectus were issued and outstanding as of June 30, 2025 (without taking into account beneficial ownership or stock exchange limitations), such shares would represent approximately 85.5% of total number of shares of our fully-diluted Common Stock outstanding and approximately 86.2% of the total number of shares of our fully-diluted Common Stock outstanding held by non-affiliates. This prospectus provides you with a general description of such securities and the general manner in which Keystone may offer or sell the securities. More specific terms of any securities that Keystone may offer or sell may be provided in a prospectus supplement that describes, among other things, the specific amounts and prices of the securities being offered and the terms of the offering. The prospectus supplement may also add, update or change information contained in this prospectus. Keystone may offer, sell or distribute all or a portion of the shares of our Common Stock acquired under the Keystone Purchase Agreements and hereby registered publicly or through private transactions at prevailing market prices or at negotiated prices. We will bear all costs, expenses and fees in connection with the registration of the shares of our Common Stock, including with regard to compliance with state securities or “blue sky” laws